Business
Cantargia’s Announces Publication of Clinical Data Demonstrating Potential of Nadunolimab Plus Pembrolizumab in Solid Tumors
LUND, SE / ACCESS Newswire / May 6, 2025 / Cantargia (STO:CANTA) Results published in the peer-reviewed journal Investigational New Drugs Study in heavily pre-treated patients with solid tumor indications who had progressed on prior immune checkpoint ...
About this update from Cantargia Ab
[{"type":"text","content":"LUND, SE / ACCESS Newswire / May 6, 2025 / Cantargia (STO:CANTA)","length":64,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Results published in the peer-reviewed journal Investigational New Drugs","length":72,"tagName":"p"}]},{"val":[{"type":"text","content":"Study in heavily pre-treated patients with solid tumor indications who had progressed on prior immune checkpoint inhibitors","length":123,"tagName":"p"}]},{"val":[{"type":"text","content":"Median overall survival of 19.7 months, with greatest survival benefit in patients with high baseline levels of infiltrating immune cells in the tumor microenvironment","length":167,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":362,"olType":false},{"type":"text","content":"Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced the publication of results from a clinical trial with nadunolimab in combination with pembrolizumab in the journal Investigational New Drugs. 15 heavily pre-treated patients with solid tumor indications who had previously progressed on immune checkpoint inhibitors were treated with nadunolimab and pembrolizumab. The trial showed an acceptable safety profile, with encouraging median survival times, especially in patients with a high level of immune cell infiltration in the tumor. These clinical data suggest a unique role of nadunolimab acting on immune cells in the tumor microenvironment.","length":660,"tagName":"p"},{"type":"text","content":""The vast number of patients whose cancer progresses on immunotherapy such as pembrolizumab have limited treatment options. These data, showing a long median survival with nadunolimab plus pembrolizumab, suggests that this combination may offer a new way to treat these high need patients." said Dr Roger Cohen from University of Pennsylvania.","length":353,"tagName":"p"},{"type":"text","content":"Immune checkpoint therapies targeting PD1, including pembrolizumab, have been some of the most transformative cancer treatments. These therapies are, however, subject to resistance mechanisms leading to loss of efficacy with time and many patients do not respond at all. The published data from the CIRIFOUR clinical trial of nadunolimab in combination with pembrolizumab in 15 patients highlights a unique opportunity to use nadunolimab in patients that have lost response to i...